Validation Study of an Advanced Blood Pressure Monitor

NCT ID: NCT04030494

Last Updated: 2019-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

218 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-13

Study Completion Date

2019-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed clinical study aims to validate the effectiveness of the WPM04 blood pressure monitor developed by Withings as a diagnostic tool for cardiovascular disorders.

The detection of cardiovascular disorders is oriented along three axes, namely the measurement of blood pressure, the identification of rhythm disorders such as atrial fibrillation and the identification of heart murmur indicating valvular heart disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Hypertension Valvular Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood pressure (BP)

Group for the validation of blood pressure measurement by the device

Group Type OTHER

BP measurement

Intervention Type DIAGNOSTIC_TEST

sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation

VHD detection

Intervention Type DIAGNOSTIC_TEST

phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Atrial fibrillation (AF)

Group for the validation of detection of AF by the device

Group Type OTHER

AF detection

Intervention Type DIAGNOSTIC_TEST

single lead ECG with Withings WPM04 and 12 lead ECG

VHD detection

Intervention Type DIAGNOSTIC_TEST

phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Valvular heart disease (VHD)

Group for the validation of detection of VHD by the device

Group Type OTHER

BP measurement

Intervention Type DIAGNOSTIC_TEST

sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation

AF detection

Intervention Type DIAGNOSTIC_TEST

single lead ECG with Withings WPM04 and 12 lead ECG

VHD detection

Intervention Type DIAGNOSTIC_TEST

phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BP measurement

sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation

Intervention Type DIAGNOSTIC_TEST

AF detection

single lead ECG with Withings WPM04 and 12 lead ECG

Intervention Type DIAGNOSTIC_TEST

VHD detection

phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female over 18 years old,
* Subject who signed the consent form,
* Subject affiliated to a social security scheme or entitled.

Exclusion Criteria

* Underage subject;
* Subject who refused to participate in the study;
* Subject participating in other research or clinical studies;
* Subject with body mass index greater than 35 kg/m2;
* Subject in linguistic or psychic incapacity to sign an informed consent;
* Subject with congenital cardiomyopathy;
* Subject with aorto-venous fistula;
* Subject with pulmonary pathology that may degrade the quality of the recording;
* Subject presenting a serious pathology compromising the realization of the examinations envisaged in the test;
* Subject with an arm injury incompatible with the use of an armband sphygmomanometer;
* Subject receiving an intravenous perfusion on the left arm;
* Subject with electrical stimulation by pacemaker, implantable cardioverter-defibrillator;
* Subject with prosthetic heart valve;
* Subject under kidney dialysis;
* Hemodynamically unstable subject (acute heart failure or cardiac assistance).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinact

OTHER

Sponsor Role collaborator

Withings

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinique AXIUM Centre de cardiologie

Aix-en-Provence, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A02847-48

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Withings ECG-app Study
NCT05316350 COMPLETED NA
VL-3 Training Study
NCT05356754 COMPLETED NA
Personal BP - CAI Study
NCT06492746 RECRUITING NA